Academic Journal
Προβολή σε EDS

Examining the species-specificity of rhesus macaque cytomegalovirus (RhCMV) in cynomolgus macaques.

Λεπτομέρειες βιβλιογραφικής εγγραφής
Τίτλος: Examining the species-specificity of rhesus macaque cytomegalovirus (RhCMV) in cynomolgus macaques.
Συγγραφείς: Marsh AK; Department of Immunology, University of Toronto, Toronto, ON, Canada., Ambagala AP; Department of Microbiology, Mount Sinai Hospital, Toronto, ON, Canada; Department of Medicine, University of Toronto, Toronto, ON, Canada., Perciani CT; Department of Immunology, University of Toronto, Toronto, ON, Canada., Russell JN; Department of Immunology, University of Toronto, Toronto, ON, Canada., Chan JK; Department of Microbiology, Mount Sinai Hospital, Toronto, ON, Canada., Janes M; National HIV & Retrovirology Laboratories, National HIV and Retrovirology Laboratories, Public Health Agency of Canada, Ottawa, ON, Canada., Antony JM; Department of Microbiology, Mount Sinai Hospital, Toronto, ON, Canada., Pilon R; National HIV & Retrovirology Laboratories, National HIV and Retrovirology Laboratories, Public Health Agency of Canada, Ottawa, ON, Canada., Sandstrom P; National HIV & Retrovirology Laboratories, National HIV and Retrovirology Laboratories, Public Health Agency of Canada, Ottawa, ON, Canada., Willer DO; Department of Microbiology, Mount Sinai Hospital, Toronto, ON, Canada; Department of Medicine, University of Toronto, Toronto, ON, Canada., MacDonald KS; Department of Immunology, University of Toronto, Toronto, ON, Canada; Department of Medicine, University of Toronto, Toronto, ON, Canada.
Πηγή: PloS one [PLoS One] 2015 Mar 30; Vol. 10 (3), pp. e0121339. Date of Electronic Publication: 2015 Mar 30 (Print Publication: 2015).
Τύπος έκδοσης: Evaluation Study; Journal Article; Research Support, Non-U.S. Gov't
Γλώσσα: English
Στοιχεία περιοδικού: Publisher: Public Library of Science Country of Publication: United States NLM ID: 101285081 Publication Model: eCollection Cited Medium: Internet ISSN: 1932-6203 (Electronic) Linking ISSN: 19326203 NLM ISO Abbreviation: PLoS One Subsets: MEDLINE
Imprint Name(s): Original Publication: San Francisco, CA : Public Library of Science
Ιατρικοί όροι (MeSH): Cytomegalovirus/*genetics , Genetic Vectors/*genetics , Macaca fascicularis/*virology , Viral Vaccines/*pharmacology, Genetic Vectors/administration & dosage ; Green Fluorescent Proteins/genetics ; Green Fluorescent Proteins/metabolism ; Saliva/virology ; Urine/virology ; Viral Vaccines/administration & dosage ; Animals ; Blotting, Western ; Immunophenotyping ; Male ; Species Specificity
Περίληψη: Cytomegalovirus (CMV) is a highly species-specific virus that has co-evolved with its host over millions of years and thus restricting cross-species infection. To examine the extent to which host restriction may prevent cross-species research between closely related non-human primates, we evaluated experimental infection of cynomolgus macaques with a recombinant rhesus macaque-derived CMV (RhCMV-eGFP). Twelve cynomolgus macaques were randomly allocated to three groups: one experimental group (RhCMV-eGFP) and two control groups (UV-inactivated RhCMV-eGFP or media alone). The animals were given two subcutaneous inoculations at week 0 and week 8, and a subset of animals received an intravenous inoculation at week 23. No overt clinical or haematological changes were observed and PBMCs isolated from RhCMV-eGFP inoculated animals had comparable eGFP- and IE-1-specific cellular responses to the control animals. Following inoculation with RhCMV-eGFP, we were unable to detect evidence of infection in any blood or tissue samples up to 4 years post-inoculation, using sensitive viral co-culture, qPCR, and Western blot assays. Co-culture of urine and saliva samples demonstrated the presence of endogenous cynomolgus CMV (CyCMV) cytopathic effect, however no concomitant eGFP expression was observed. The absence of detectable RhCMV-eGFP suggests that the CyCMV-seropositive cynomolgus macaques were not productively infected with RhCMV-eGFP under these inoculation conditions. In a continued effort to develop CMV as a viral vector for an HIV/SIV vaccine, these studies demonstrate that CMV is highly restricted to its host species and can be highly affected by laboratory cell culture. Consideration of the differences between lab-adapted and primary viruses with respect to species range and cell tropism should be a priority in evaluating CMV as vaccine vector for HIV or other pathogens at the preclinical development stage.
Σχόλια: Erratum in: PLoS One. 2015 May 14;10(5):e0128733. doi: 10.1371/journal.pone.0128733.. (PMID: 25973867)
References: J Virol Methods. 2002 Jul;104(2):135-46. (PMID: 12088823)
J Virol. 2012 Apr;86(7):3626-34. (PMID: 22258257)
N Engl J Med. 2001 May 3;344(18):1366-71. (PMID: 11333993)
Invest Ophthalmol Vis Sci. 2002 Feb;43(2):358-63. (PMID: 11818377)
PLoS One. 2013;8(10):e76267. (PMID: 24146849)
Nat Biotechnol. 2011 Nov;29(11):1019-23. (PMID: 22002653)
J Virol. 2011 Dec;85(24):12995-3009. (PMID: 21994460)
Virol J. 2008;5:139. (PMID: 19014498)
J Med Virol. 1984;14(4):305-12. (PMID: 6096500)
J Immunol. 2011 Aug 15;187(4):1722-32. (PMID: 21765018)
Proc Natl Acad Sci U S A. 2008 Dec 16;105(50):19950-5. (PMID: 19064925)
J Virol. 2001 May;75(10):4854-70. (PMID: 11312357)
Virology. 2011 Mar 30;412(1):125-35. (PMID: 21272907)
J Clin Microbiol. 2008 Mar;46(3):882-6. (PMID: 18216215)
Arch Virol. 1984;82(1-2):125-8. (PMID: 6093744)
J Virol. 2012 Sep;86(17):8959-73. (PMID: 22718821)
Arch Virol. 2001;146(9):1723-38. (PMID: 11699958)
Science. 2013 May 24;340(6135):1237874. (PMID: 23704576)
Genome Res. 2011 Oct;21(10):1746-56. (PMID: 21862625)
J Virol. 2003 May;77(10):5749-58. (PMID: 12719568)
J Virol. 2003 May;77(9):5073-83. (PMID: 12692210)
J Exp Med. 2005 Sep 5;202(5):673-85. (PMID: 16147978)
J Virol. 2000 Sep;74(17):8140-50. (PMID: 10933725)
J Pediatr. 1996 Mar;128(3):347-52. (PMID: 8774502)
Arch Virol. 2013 May;158(5):955-65. (PMID: 23232747)
J Infect Dis. 1984 Dec;150(6):952-3. (PMID: 6094678)
J Virol. 1999 Nov;73(11):9576-83. (PMID: 10516066)
J Virol. 1996 Dec;70(12):8833-49. (PMID: 8971012)
Clin Infect Dis. 2004 Jul 15;39(2):155-61. (PMID: 15307021)
J Infect Dis. 2002 Jul 1;186(1):15-22. (PMID: 12089657)
J Mol Biol. 1995 Mar 31;247(3):443-58. (PMID: 7714900)
Br J Dermatol. 2006 Feb;154(2):365-7. (PMID: 16433812)
J Virol. 2000 Nov;74(22):10401-6. (PMID: 11044084)
J Gen Virol. 2008 Feb;89(Pt 2):359-68. (PMID: 18198366)
Bioinformatics. 2010 Mar 1;26(5):589-95. (PMID: 20080505)
Nat Med. 2009 Mar;15(3):293-9. (PMID: 19219024)
Nature. 1970 Jul 11;227(5254):168-70. (PMID: 4316953)
J Gen Virol. 2003 Jan;84(Pt 1):17-28. (PMID: 12533697)
J Infect Dis. 2003 Sep 1;188(5):678-89. (PMID: 12934184)
Proc Natl Acad Sci U S A. 2003 Nov 25;100(24):14223-8. (PMID: 14623981)
Epidemiol Infect. 1988 Dec;101(3):483-94. (PMID: 2850934)
J Med Virol. 1995 Aug;46(4):387-96. (PMID: 7595418)
J Gen Virol. 2004 May;85(Pt 5):1301-12. (PMID: 15105547)
Proc Natl Acad Sci U S A. 2003 Dec 9;100(25):14976-81. (PMID: 14657367)
J Gen Virol. 2011 May;92(Pt 5):1005-20. (PMID: 21270288)
Lancet. 1998 Oct 17;352(9136):1280-1. (PMID: 9788461)
Transfusion. 2007 Jan;47(1):162-70. (PMID: 17207245)
J Virol. 2000 Aug;74(16):7656-65. (PMID: 10906222)
Int J Primatol. 2008;29(5):1295-1311. (PMID: 19122840)
Am J Primatol. 2003 Mar;59(3):123-8. (PMID: 12619046)
Science. 2010 Apr 2;328(5974):102-6. (PMID: 20360110)
Proc Soc Exp Biol Med. 1974 Mar;145(3):794-801. (PMID: 4131945)
Virology. 2003 Nov 25;316(2):221-33. (PMID: 14644605)
Curr Top Microbiol Immunol. 1990;154:125-69. (PMID: 2161319)
Hum Immunol. 2004 May;65(5):500-6. (PMID: 15172450)
J Virol. 2012 Jun;86(11):6354-7. (PMID: 22491451)
J Infect Dis. 1987 Apr;155(4):655-60. (PMID: 3029241)
J Virol. 2006 Apr;80(8):4179-82. (PMID: 16571834)
Am J Primatol. 2013 Feb;75(2):135-44. (PMID: 23165690)
J Virol. 2002 Sep;76(18):9493-504. (PMID: 12186931)
Nature. 2011 May 26;473(7348):523-7. (PMID: 21562493)
J Virol. 2003 Jun;77(12):6620-36. (PMID: 12767982)
J Virol. 2011 May;85(10):5105-14. (PMID: 21389128)
J Infect Dis. 1984 Dec;150(6):953-6. (PMID: 6094679)
PLoS One. 2012;7(2):e30087. (PMID: 22347999)
EMBO J. 2006 Jun 7;25(11):2634-42. (PMID: 16688216)
J Virol. 1973 Jun;11(6):998-1003. (PMID: 4351465)
J Virol. 2003 Jun;77(11):6546-50. (PMID: 12743312)
J Virol. 2010 Mar;84(5):2304-17. (PMID: 20032177)
Grant Information: 107743 Canada Canadian Institutes of Health Research
Substance Nomenclature: 0 (Viral Vaccines)
0 (enhanced green fluorescent protein)
147336-22-9 (Green Fluorescent Proteins)
Entry Date(s): Date Created: 20150331 Date Completed: 20160321 Latest Revision: 20191210
Update Code: 20260130
PubMed Central ID: PMC4378995
DOI: 10.1371/journal.pone.0121339
PMID: 25822981
Βάση Δεδομένων: MEDLINE
Περιγραφή
ISSN:1932-6203
DOI:10.1371/journal.pone.0121339